Xia WangThompson G. RobinsonTsong-Hai LeeQiang LiHisatomi ArimaPhilip M. BathLaurent BillotJoseph BroderickAndrew M. DemchukGeoffrey DonnanJong S. KimPablo LavadosRichard I. LindleySheila O. MartinsVeronica V. OlavarriaJeyaraj D. PandianMark W. ParsonsOctavio M. Pontes-NetoStefano RicciVijay K. SharmaNguyen H. ThangJi-Guang WangMark WoodwardCraig S. AndersonJohn Chalmers2022-09-262022-09-262017https://investigadores.udd.cl/handle/123456789/272910.1001/jamaneurol.2017.22862-s2.0-85034646950WOS:00041511760000980 years oldintravenous alteplaseplasminogen-activator0.6 mg/kgthrombolytic therapystatistical-analysisenhanced controlchinese patientsj-acthypertensionLow-Dose vs Standard-Dose Alteplase for Patients With Acute Ischemic Stroke Secondary Analysis of the ENCHANTED Randomized Clinical TrialResource Types::text::journal::journal article